Note 2 - Summary of Significant Accounting Policies and Basis of Presentation - Restatement Adjustments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Research and development	$ 5,783,865	$ 5,484,145
Net loss	(7,433,608)	(6,851,689)
Total operating expenses	7,922,106	6,984,699
Loss from operations	(7,922,106)	(6,984,699)
Accrued expenses and other current liabilities	(4,886,395)	761,736
Net cash used in operating activities	$ (11,725,809)	$ (7,951,397)
Basic and diluted (in dollars per share)	$ (0.25)	$ (0.31)
Previously Reported [Member]
Research and development		$ 5,234,999
Net loss		(6,602,543)
Total operating expenses		6,735,553
Loss from operations		(6,735,553)
Accrued expenses and other current liabilities		512,590
Net cash used in operating activities		$ (7,951,397)
Basic and diluted (in dollars per share)		$ (0.3)
Revision of Prior Period, Adjustment [Member]
Research and development		$ 249,146
Net loss		(249,146)
Total operating expenses		249,146
Loss from operations		(249,146)
Accrued expenses and other current liabilities		249,146
Net cash used in operating activities		$ 0
Basic and diluted (in dollars per share)		$ (0.01)